2417370-68-2

L1BC8 Chemical Structure
2417370-68-2

Chemical Structure

L1BC8

  • CAS No.: 2417370-68-2
  • Formula:C86H98F2N16O18S2
  • Molecular Weight:1745.92

InChIKey: QLICKLWRUHDJHI-PXYLJKOWSA-N

SMILES: O=C(OCC1=CC=C(NC([C@@H](NC(C2(CCC2)C(NCCCCCN3C(C=CC3=O)=O)=O)=O)CCCNC(N)=O)=O)C=C1)NC4=CC(CCOCC(N[C@@H](C(C)(C)C)C(N5[C@H](C(NCC6=CC=C(C7=C(C)N=CS7)C=C6)=O)C[C@@H](O)C5)=O)=O)=CC(OCCNC(C8=C(CS(=O)(C)=O)C=C(C(N(C9=NC=C(F)C=C9F)C%10)=C8)C%11=CN(C)C(C%12=C%11C%10=CN%12)=O)=O)=C4

Biological Activity: L1BC8 (Compound 13a) is a drug-linker conjugate for ADC. L1BC8 is obtained by conjugating a BRD4 PROTAC degrader with a peptidomimetic protease-cleavable linker for the preparation of ADC, which can be conjugated to STEAP1 antibodies and CLL1 antibodies, respectively. L1BC8 can be used in research related to prostate cancer and acute myeloid leukemia[1].

Cat. No. Product Name Purity Description Pricing
HY-164995
L1BC8 99.20% L1BC8 (Compound 13a) is a drug-linker conjugate for ADC. L1BC8 is obtained by conjugating a BRD4 PROTAC degrader with a peptidomimetic protease-cleavable linker for the preparation of ADC, which can be conjugated to STEAP1 antibodies and CLL1 antibodies, respectively. L1BC8 can be used in research related to prostate cancer and acute myeloid leukemia.
Pricing 
Expand Hide
loading...
/
  • /
loading...
Size Price
Stock Quantity Availability Operate
/
In-stock
(Estimated to ship on )
(Estimated to ship TODAY)
Estimated to ship on
(Estimated to ship TODAY)

Amount:

USD 0.00

This product is a controlled substance and not for sale in your territory.

This product is not for sale in your territory.

This compound is listed in the SVHC (Substances of Very High Concern) candidate list of ECHA (European Chemicals Agency).

Pricing 
Expand Hide

References